Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug:61:152220.
doi: 10.1016/j.semarthrit.2023.152220. Epub 2023 May 5.

Domain reporting in Systemic Sclerosis-Related Digital Ulcers: An OMERACT Scoping Review

Affiliations

Domain reporting in Systemic Sclerosis-Related Digital Ulcers: An OMERACT Scoping Review

Michael Hughes et al. Semin Arthritis Rheum. 2023 Aug.

Abstract

Background: Digital ulcers (DUs) are a major cause of pain and disability in patients with systemic sclerosis (SSc). The aim of this scoping review was to evaluate the outcome domains used in studies of SSc-associated DUs.

Methods: Electronic databases (EMBASE, MEDLINE and the Cochrane Library) were searched for articles written (1947 onwards) in English relating to SSc-DUs. A minimum of 15 participants for studies of imaging and 25 participants for questionnaire-based studies was required for inclusion. Information on all primary and secondary domains was extracted.

Results: 4869 manuscripts were identified, of which 40 met the eligibility criteria and were included in the synthesis. Most studies were randomized controlled trials (n=13), or prospective (n=12)/retrospective (n=8) observational studies. Interventions included oral or intravenous drugs (n=25), topical/local treatments (n=5), and surgical interventions (n=2). Approximately half the studies assessed either the count/number of DUs (n=23) and/or improvement in DUs (n=20). Functional impact of DUs was examined in 25% (n=10) of studies. Other domains were related to complications of DUs (n=7), pain (n=6), health-related quality of life (n=4), microvascular assessment/pathophysiology (n=4), global assessment of DUs (n=2), and histopathology (n=1).

Conclusion: This scoping review identified a broad range of disease-related domains used to study SSc-DUs. There is significant heterogeneity in these domains. These data will inform the ongoing work of the OMERACT Vascular Disease in Systemic Sclerosis Working Group to define a core set of disease broad domains to capture the burden of DUs in SSc.

Keywords: Clinical Trials; Digital ulcers; Domains, OMERACT, Scoping review; Outcomes; Scleroderma; Systemic sclerosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr Hughes reports speaking fees from Actelion Pharmaceuticals, Eli Lilly, Janssen, and Pfizer. Research funding from Janssen. Member of a Data and Safety Monitoring Board for Certa Therapeutics. Dr. Pauling reports grants and personal fees from Janssen, outside the submitted work; Dr Pauling reports personal fees from Astra Zenaca, Boehringer Ingelheim, Sojournix Pharma and Permeatus, Inc. Dr Proudman reports receiving funds for the following activities: advisory board: Boehringer-Ingelheim, Janssen, Gossamer. Research Support: Janssen. Dr. Merkel reports receiving funds for the following activities in the past 2 years: Consulting: AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, Cabaletta, ChemoCentryx, CSL Behring, Dynacure, EMDSerono, Forbius, Genentech/Roche, GlaxoSmithKline, InflaRx, Jannsen, Jubilant, Kiniksa, Kyverna, Magenta, MiroBio, Mitsubishi, Neutrolis, Novartis, NS Pharma, Pfizer, Q32, Regeneron, Sparrow, Takeda, Vistera. Research Support: AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Eicos, Electra, Forbius, Genentech/Roche, GlaxoSmithKline, InflaRx, Sanofi, Star, Takeda. Stock options: Kyverna. Royalties: UpToDate. Professor Herrick reports research funding from Gesynta Pharma, consultancies with Arena, Boehringer-Ingelheim, Camurus, CSL Behring, Galderma, Gesynta Pharma and speaker's fees from Janssen.

Publication types

Supplementary concepts

LinkOut - more resources